Antineoplastic resistance

NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020

Retrieved on: 
Friday, May 15, 2020
Medical specialties, Medicine, Thymidylate synthase, Clinical medicine, Damage-associated molecular pattern, PD-L1, Cancer, Cancer treatments, Mutation, Antineoplastic resistance, Thymidylate synthase inhibitor

In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.

Key Points: 
  • In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.
  • These new in vitro data presented at AACR suggest that Acelarin may also have a potential immunomodulatory role.
  • Acelarin was found to cause the release of Damage Associated Molecular Patterns, or DAMPs, and increase the expression of PD-L1 on cancer cells.
  • NUC-3373 was found to be a potent inhibitor of thymidylate synthase, which results in DNA damage of cancer cells.

The global gene amplification technologies market at a CAGR of over 9% during the forecast period

Retrieved on: 
Monday, September 16, 2019
Oncology, Medicine, Clinical medicine, Health, Cancer, Chemotherapy, Antineoplastic resistance

Global Gene Amplification Technologies Market: About this market

Key Points: 
  • Global Gene Amplification Technologies Market: About this market
    This gene amplification technologies market analysis considers sales from medical and pharmaceutical, forensic and identity testing, agricultural and food safety, and other applications.
  • Also, our global gene amplification technologies market report looks at factors such as increasing genomic research, substantial adoption of gene amplification technologies in targeted cancer therapies, and low cost of genetic sequencing.
  • Global Gene Amplification Technologies Market: Overview
    Adoption of gene amplification kits in targeted cancer therapies is being witnessed due to the increasing demand for alternative treatments to chemotherapy.
  • Thus, the increasing development of such therapies to treat various cancers, such as colorectal, cervical, and breast cancer, is expected to trigger the adoption of gene amplification technologies and lead to the expansion of the global gene amplification technologies market at a CAGR of over 9% during the forecast period.

Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy

Retrieved on: 
Wednesday, March 27, 2019
RTT, Medicine, Health, Medical specialties, Trastuzumab, Cancer, Treatment of cancer, Breast cancer, Metastatic breast cancer, Antineoplastic resistance

NEW YORK, March 27, 2019 /PRNewswire/ -- Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.

Key Points: 
  • NEW YORK, March 27, 2019 /PRNewswire/ -- Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.
  • The United States undertook 67 percent of these gene therapy clinical trials, with most of them targeting cancer.
  • Oncoprex interrupts cell signalling pathways that cause the replication and proliferation of cancer cells, re-establishes pathways for programmed cell death in cancer cells, and modulates the immune response against cancer.
  • A biosimilar to Herceptin, TRAZIMERA targets certain proteins preventing cancer cell division and growth targeting breast cancer treatments.

Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy

Retrieved on: 
Wednesday, March 27, 2019
RTT, Health, Medicine, Medical specialties, Trastuzumab, Cancer, Treatment of cancer, Breast cancer, Metastatic breast cancer, Antineoplastic resistance

NEW YORK, March 27, 2019 /PRNewswire/ -- Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.

Key Points: 
  • NEW YORK, March 27, 2019 /PRNewswire/ -- Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.
  • The United States undertook 67 percent of these gene therapy clinical trials, with most of them targeting cancer.
  • Oncoprex interrupts cell signalling pathways that cause the replication and proliferation of cancer cells, re-establishes pathways for programmed cell death in cancer cells, and modulates the immune response against cancer.
  • A biosimilar to Herceptin, TRAZIMERA targets certain proteins preventing cancer cell division and growth targeting breast cancer treatments.